Pharmaceuticals, Biotechnology and Life Sciences
United States Food and Drug Administration (FDA) has approved Lonsurf (trifluridine and tipiracil) tablets for the treatment of patients with metastatic colorectal cancer who have been previously…
Allergan plc has confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction.
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management and control in Ghana
U.S. Food and Drug Administration (FDA) has approved BMS’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection including total lymphadenectomy.
Plandaí Biotechnology, Inc., has executed an Exclusive Distribution Agreement with Bal Pharma Ltd., an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients.
Oxford BioMedica plc, a gene and cell therapy group, has announced that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica’s LentiVector platform technology patents.
Premaitha Health PLC, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) confirms that Chief Medical Officer, Dr William Denman, will join the Board of Premaitha as an Executive Director on 1 November 2015.
In the last five years of life, total health care spending for people with dementia was more than a quarter-million…
GW Pharmaceuticals plc, has signed a Memorandum of Understanding (MOU) with the Government of New South Wales (NSW) in Australia to progress a research program for Epidiolex (cannabidiol or CBD) and cannabidivarin (CBDV) in children with severe, drug resistant childhood epilepsy.
Allergan plc and Ironwood Pharmaceuticals, Inc. have announced that Allergan has acquired rights to Constella (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to Linzess (linaclotide) in Mexico from Almirall.